GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cumberland Pharmaceuticals Inc (NAS:CPIX) » Definitions » PS Ratio

Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) PS Ratio : 0.62 (As of Apr. 30, 2024)


View and export this data going back to 2009. Start your Free Trial

What is Cumberland Pharmaceuticals PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Cumberland Pharmaceuticals's share price is $1.70. Cumberland Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.75. Hence, Cumberland Pharmaceuticals's PS Ratio for today is 0.62.

The historical rank and industry rank for Cumberland Pharmaceuticals's PS Ratio or its related term are showing as below:

CPIX' s PS Ratio Range Over the Past 10 Years
Min: 0.52   Med: 2.39   Max: 3.51
Current: 0.63

During the past 13 years, Cumberland Pharmaceuticals's highest PS Ratio was 3.51. The lowest was 0.52. And the median was 2.39.

CPIX's PS Ratio is ranked better than
83.83% of 1002 companies
in the Drug Manufacturers industry
Industry Median: 2.185 vs CPIX: 0.63

Cumberland Pharmaceuticals's Revenue per Sharefor the three months ended in Dec. 2023 was $0.66. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $2.75.

Warning Sign:

Cumberland Pharmaceuticals Inc revenue per share is in decline over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Cumberland Pharmaceuticals was -4.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 3.90% per year. During the past 5 years, the average Revenue per Share Growth Rate was 8.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was 4.20% per year.

During the past 13 years, Cumberland Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 47.30% per year. The lowest was -7.40% per year. And the median was 4.55% per year.

Back to Basics: PS Ratio


Cumberland Pharmaceuticals PS Ratio Historical Data

The historical data trend for Cumberland Pharmaceuticals's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cumberland Pharmaceuticals PS Ratio Chart

Cumberland Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.31 1.19 1.93 0.78 0.65

Cumberland Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.78 0.71 0.52 0.69 0.65

Competitive Comparison of Cumberland Pharmaceuticals's PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cumberland Pharmaceuticals's PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's PS Ratio distribution charts can be found below:

* The bar in red indicates where Cumberland Pharmaceuticals's PS Ratio falls into.



Cumberland Pharmaceuticals PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Cumberland Pharmaceuticals's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.70/2.746
=0.62

Cumberland Pharmaceuticals's Share Price of today is $1.70.
Cumberland Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.75.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Cumberland Pharmaceuticals  (NAS:CPIX) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Cumberland Pharmaceuticals PS Ratio Related Terms

Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, RediTrex, Sancuso, Vaprisol and Vibativ.
Executives
Todd M. Anthony officer: Vice Pres Organizational Dev 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Chris T. Bitterman officer: Vice Pres Sales & Marketing 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Joseph C Galante director 111 TENTH AVENUE, SUITE 200, NASHVILLE TN 37203
James Jones director 2525 WEST END AVE., SUITE 950, NASHVILLE TN 37203
Kenneth Krogulski director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Caroline Young director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Brown Martin S Jr director 850 DIXIE HIGHWAY, LOUISVILLE KY 40210
A J Kazimi director, 10 percent owner, officer: Chairman and CEO 1207 17TH AVENUE SUITE 103, NASHVILLE TN 37212
Martin E Cearnal director 31 UPPER MOUNTAIN AVENUE, APARTMENT 2, MONTCLAIR NJ 07042
John M. Hamm officer: Chief Financial Officer 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Gordon R Bernard officer: Senior Vice President 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Joey A Jacobs director 830 CRESCENT CENTER DRIVE, SUITE 610, FRANKLIN TN 37067
Michael Bonner officer: Chief Financial Officer 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Jonathan Griggs director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Thomas R Lawrence director 1880 ELLINGTON WAY, AUBURN AL 36830